推薦產品
重組細胞
expressed in mouse NSO cells
品質等級
形狀
solution
比活性
≥7,500 units/μg protein
分子量
83 kDa
雜質
≤1.0 EU/μg Endotoxin
運輸包裝
wet ice
儲存溫度
−20°C
一般說明
α-L-艾杜糖苷酸酶 (IDUA) 定位于人染色体4p16.3。成熟的IDUA蛋白被糖基化，并包含三糖磷酸异构酶（TIM）桶状结构域、β夹心式螺旋-环-螺旋区域和免疫球蛋白样结构域。α-L-艾杜糖苷酸酶被归类为糖苷水解酶（GH）家族39。
應用
α-L-艾杜糖醛酸酶可用于新生儿 a-L-艾杜糖醛酸酶缺乏症的白细胞测定。
生化／生理作用
α-L-艾杜糖苷酸酶突变与粘多糖贮积病I型（MPS I）有关。该酶的缺陷导致皮肤素和硫酸乙酰肝素的积累。MPS I的病理生理学伴随着颅骨变形、智力低下和疝气。
在溶酶体降解过程中，α-L-艾杜糖苷酸酶（Iduronidase ）起着至关重要的作用。它水解糖胺聚糖（GAG）（包括硫酸皮肤素和硫酸乙酰肝素） 中非还原末端的α L-艾杜糖醛酸残基。
催化硫酸皮肤素中未硫酸化的 L -艾杜糖苷键的水解
物理性質
在 SDS-PAGE 还原条件下，表达为 C-末端组氨酸标记蛋白（残基 1-653），其含钙核分子量为 71 kDa，在约 83 kDa 处迁移。
單位定義
一个单元将在-25°C pH 3.5 下每分钟从 4-甲基伞形酮-α-L-艾杜糖苷酸生成 1 皮摩尔的 4-甲基伞形酮。
外觀
40 mM 醋酸钠、400 mM NaCl 和 20% (v/v) 甘油溶液 (pH 5.0)
儲存類別代碼
10 - Combustible liquids
水污染物質分類（WGK）
WGK 1
閃點（°F）
Not applicable
閃點（°C）
Not applicable
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。
客戶也查看了
Vassili Valayannopoulos et al.
Rheumatology (Oxford, England), 50 Suppl 5, v49-v59 (2012-01-11)
Better understanding of disease pathophysiology, improved supportive care and availability of disease-specific treatments for some of the mucopolysaccharidosis (MPS) disorders have greatly improved the outlook for patients with MPS disorders. Optimal management of these multisystemic disorders involves a multidisciplinary team
Human kidney alpha-L-iduronidase: purification and characterization.
L H Rome et al.
Archives of biochemistry and biophysics, 189(2), 344-353 (1978-08-01)
Francesca Gatto et al.
Stem cells and development, 21(9), 1466-1477 (2012-01-28)
Mucopolysaccharidosis type I (MPS IH; Hurler syndrome) is a rare genetic disorder that is caused by mutations in the α-L-iduronidase (IDUA) gene, resulting in the deficiency of IDUA enzyme activity and intra-cellular accumulation of glycosaminoglycans. A characteristic skeletal phenotype is
Haiying Bie et al.
Nature chemical biology, 9(11), 739-745 (2013-09-17)
Mucopolysaccharidosis type I (MPS I), caused by mutations in the gene encoding α-L-iduronidase (IDUA), is one of approximately 70 genetic disorders collectively known as the lysosomal storage diseases. To gain insight into the basis for MPS I, we crystallized human
Patricia I Dickson et al.
Molecular genetics and metabolism, 106(1), 68-72 (2012-03-10)
Intrathecal enzyme replacement therapy is an experimental option to treat central nervous system disease due to lysosomal storage. Previous work shows that MPS I dogs receiving enzyme replacement with recombinant human alpha-l-iduronidase into the cisterna magna showed normal brain glycosaminoglycan
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務